Quick Answer
ImmunityBio, Inc. reported Total Assets of $501.90 million for the year ending 2025.
- ImmunityBio, Inc. showed an increase of +31.1% in Total Assets from 2024 to 2025.
- This data is from ImmunityBio, Inc.'s annual report (Form 10-K), filed with the SEC on February 23, 2026.
- XBRL data for this metric is available from 2015 to 2025 (11 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q4 2014: $60.83 million | Q2 2015: $132.56 million | Q3 2015: $370.19 million | Q1 2016: $357.43 million | Q2 2016: $342.94 million | Q3 2016: $332.41 million | Q1 2017: $303.68 million | Q2 2017: $301.62 million | Q3 2017: $277.74 million | Q1 2018: $229.85 million | Q2 2018: $211.43 million | Q3 2018: $201.64 million | Q1 2019: $208.26 million | Q2 2019: $175.70 million | Q3 2019: $160.21 million | Q1 2020: $127.02 million | Q2 2020: $196.16 million | Q3 2020: $180.54 million | Q1 2021: $209.43 million | Q2 2021: $246.30 million | Q3 2021: $214.42 million | Q1 2022: $389.59 million | Q2 2022: $317.72 million | Q3 2022: $352.94 million | Q1 2023: $343.40 million | Q2 2023: $291.23 million | Q3 2023: $432.42 million | Q1 2024: $400.68 million | Q2 2024: $444.33 million | Q3 2024: $364.57 million | Q1 2025: $303.76 million | Q2 2025: $402.08 million | Q3 2025: $518.99 million.
- Over the full 11 years of available data (2015 to 2025), ImmunityBio, Inc.'s Total Assets has grown by 36.8%.
- Historical annual values: Fiscal year 2025: $501.90 million | Fiscal year 2024: $382.93 million | Fiscal year 2023: $504.45 million | Fiscal year 2022: $362.36 million | Fiscal year 2021: $468.91 million | Fiscal year 2020: $221.38 million | Fiscal year 2019: $143.12 million | Fiscal year 2018: $181.95 million | Fiscal year 2017: $250.44 million | Fiscal year 2016: $317.50 million | Fiscal year 2015: $366.85 million.
- Data sourced from SEC EDGAR public filings as of August 5, 2026.
Last verified: